МЕДИЦИНА, ПЕДАГОГИКА И ТЕХНОЛОГИЯ:
ТЕОРИЯ И ПРАКТИКА
ISSN: 3030-3001
SJIF 2023: 3.019, 2024: 5.444 ResearchBib IF: 13.14/ 2024
Том 3, Выпуск 5
60 https://universalpublishings.com
UDK:618.174.3–082
INNOVATIVE THERAPEUTIC STRATEGIES FOR MANAGING
POST-CASTRATION SYNDROME AFTER OVARIAN
HYPERSTIMULATION
Narkulova Soxiba Uktamovna
Samarkand State Medical University, Department of Obstetrics and Gynecology No. 3
Xudoyberdiyeva Zarina Alisher qizi
Samarkand State Medical University, Department of Obstetrics and Gynecology No. 3
Introduction: Definition and clinical importance
Post-castration syndrome
(PCS) can develop after oocyte retrieval and luteal phase; severe ovarian
hyperstimulation syndrome (OHSS) manifests as ascites, electrolyte imbalance,
ovarian enlargement, and systemic signs. Although PCS is relatively rare,
complications can be life-threatening and compromise IVF outcomes.
Etiology:
High estradiol levels, VEGF-driven vascular permeability, and prolonged luteal
activity following hCG trigger create the pathophysiological basis for PCS .
Treatment:
Conventional approaches are primarily supportive—hydration, paracentesis,
thromboprophylaxis, and cycle cancellation. These fail to modify the hormonal cascade
underlying PCS.
Emerging Strategies for PCS Management
GnRH antagonist rescue in established PCS
Studies illustrate that administering a GnRH antagonist during the luteal phase
(approximately six days post-OPU) abrupts luteal steroid production, reducing ovarian
volume, ascites, hematocrit, and WBC counts. One Greek study reported outpatient
resolution of PCS without hospitalization.
Minimizing risk via trigger modification and freeze-all strategy
•
GnRH agonist (“Lupron”) trigger with antagonist protocols
: Used
instead of hCG, this strategy significantly reduces OHSS/PCS incidence (≈85% risk
reduction).
МЕДИЦИНА, ПЕДАГОГИКА И ТЕХНОЛОГИЯ:
ТЕОРИЯ И ПРАКТИКА
ISSN: 3030-3001
SJIF 2023: 3.019, 2024: 5.444 ResearchBib IF: 13.14/ 2024
Том 3, Выпуск 5
61 https://universalpublishings.com
•
Freeze-all implementation
: By cryopreserving all embryos or oocytes
post-trigger, luteal hCG exposure from pregnancy is avoided, further decreasing PCS
incidence.
Cabergoline
Cabergoline, a dopamine agonist, attenuates VEGF-mediated vascular
permeability. Meta-analyses show that prophylactic use lowers OHSS risk without
reducing live birth rates.
In vitro maturation (IVM) to prevent stimulation entirely
IVM eliminates the need for supraphysiological gonadotropins by maturing
oocytes outside the div. It prevents OHSS/PCS and benefits PCOS patients with
comparable implantation rate.
Artificial intelligence-guided optimization
Next-generation approaches—and the future of personalized ART—include AI
tools like “ILETIA”, which use clinical and imaging data to individualize trigger-to-
retrieval timing, reducing unnecessary luteal overproduction.
Proposed Integrated Protocol
Risk stratification
•
Stratify patients during COS by follicle count (>18 high risk) and estradiol
levels.
•
For low-risk: standard antagonist + low-dose hCG trigger.
•
For high-risk: GnRH agonist trigger + freeze-all.
Luteal phase rescue
•
If PCS signs emerge (e.g. ascites, hematocrit rise), administer daily GnRH
antagonist from Day 6 post-OPU for ~7 days.
•
Optionally add cabergoline to suppress VEGF effects.
Post-cycle follow-up
•
Continue monitoring with ultrasound, laboratory testing (hematocrit,
WBC, estradiol).
•
Non-transferred embryos are cryopreserved and used in future cycles.
Future directions
•
IVM integration
for PCOS or high responders eliminates stimulation
risk.
•
AI-guided COS protocols
, optimizing gonadotropin dosage and timing
to minimize overstimulation.
Discussion and conclusion:
МЕДИЦИНА, ПЕДАГОГИКА И ТЕХНОЛОГИЯ:
ТЕОРИЯ И ПРАКТИКА
ISSN: 3030-3001
SJIF 2023: 3.019, 2024: 5.444 ResearchBib IF: 13.14/ 2024
Том 3, Выпуск 5
62 https://universalpublishings.com
Combining GnRH agonist triggers, freeze-all strategies, luteal antagonists,
cabergoline, IVM, and AI-driven scheduling provides a multi-modal strategy to prevent
and treat PCS. These approaches demonstrate strong evidence and promise better
outcomes and patient safety compared to supportive care alone. Future randomized
trials will help refine and optimize protocols for wider clinical usage.
References:
1.
Lainas TG et al.: Outpatient GnRH antagonist for established PCS
resolves hematologic and ascitic findings within 7 days
2.
Orvieto et al.: GnRH agonist trigger + freeze-all eliminates OHSS risk in
antagonist cycles with ≥18 follicles
3.
Cochrane reviews/meta-analyses: Cabergoline prophylaxis reduces OHSS
incidence via VEGF modulation
4.
De Vos et al.: In vitro maturation offers safer ART for PCOS with similar
5.
Wu et al.: AI model (“ILETIA”) enhances timing precision in stimulation,
reducing risk factors .
